Inovio Pharma’s vaccine clears first hurdle in Phase 1 Trials

A DNA-based Zika virus vaccine developed by Inovio Pharmaceuticals has proven successful in phase I open-label dose-ranging human trials. In animal studies, this vaccine was found to prevent Zika virus infection as well as brain damage. 
In the press release, the company said it is optimistic …

Protein Sciences’ Zika Vaccine moves into Phase 1 trials

Protein Sciences reported that its protein based Zika vaccine candidate is expected to move on to human clinical trials by April. Also, the team developing the vaccine in Protein Sciences is now joined by the Institute of Technology in Immunobiological of the Oswaldo Cruz Foundation. The move…